EUVIMEDObjevte EUVIMED
LeitlinieOpen access · CC BY-NC 4.0

Practical Management of Cytopenias in Patients with Myelofibrosis Adapted to the Portuguese Reality

António Medina de Almeida, Bárbara Marques, Blanca Polo, Francesca Pierdomenico, Marco Dias, Ricardo Pinto

Acta Médica Portuguesa · 2026

DOI: 10.20344/amp.24397 ↗

At a glance

Leitlinie in Acta Médica Portuguesa, 2026. Written by António Medina de Almeida and 5 co-authors. Institution: Serviço de Hematologia Clínica. Hospital da Luz Lisboa. Lisboa. Portugal. & Faculdade de Medicina. Universidade Católica Portuguesa. Lisboa. Portugal. Major MEDLINE topics: Anemia, Cytopenia, Primary Myelofibrosis. 43 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Cytopenias are a common clinical manifestation of myelofibrosis, particularly anemia. Although correcting cytopenias is essential to improve prognosis and quality of life of patients with myelofibrosis, there are few effective therapeutic options. Furthermore, there are no national guidelines for the management of cytopenias in myelofibrosis. To address this gap, a panel composed of six hematologists proposes an approach for patients with myelofibrosis and cytopenias adapted to clinical practice in Portugal, based on scientific evidence and clinical experience. Firstly, the etiology of the anemia should be identified. In patients with myelofibrosis-related anemia who have splenomegaly and/or constitutional symptoms, the use of Janus kinase inhibitors should be prioritized: momelotinib as monotherapy, or ruxolitinib in combination with an erythropoiesis-stimulating agent or danazol, depending on erythropoietin levels. In anemic patients without splenomegaly or constitutional symptoms, treatment with an erythropoiesis-stimulating agent, danazol, a combination of an immunomodulator with corticosteroid, or momelotinib, should be considered. In patients with treatment-induced anemia, the use of a Janus kinase inhibitor (with possible dose reduction in the case of ruxolitinib) in combination with an erythropoiesis-stimulating agent or danazol, or momelotinib as monotherapy should be considered. Thrombocytopenic patients eligible for Janus kinase inhibitors may receive ruxolitinib at a reduced dose, or momelotinib, the latter of which does not require dose reduction for thrombocytopenia. In thrombocytopenic patients without splenomegaly, constitutional symptoms, or anemia, the approach consists of monitoring or treatment with danazol, corticosteroids, or a combination of immunomodulator and corticosteroid, according to platelet count and hemorrhagic diathesis. Transfusion should be considered in patients with severe anemia or thrombocytopenia, diathesis, or the need for surgery. Symptomatic and analytical improvement, reduction of splenomegaly, and independence from or a significant decrease in transfusion support indicate a response to treatment. Treatment switch is warranted in cases of toxicity, failure, loss of clinical or hematological response after initial response, or disease progression. The implementation of these recommendations will help to optimize care for patients with myelofibrosis and cytopenias, improving clinical outcomes.

Subjects

MeSH terms (MEDLINE)

AnemiaCytopeniaPrimary MyelofibrosisHumansDanazolPortugalThrombocytopenia

Author keywords

AnemiaCytopeniaDisease ManagementMyelofibrosisPortugalThrombocytopenia

Substances

Danazol

Authors and institutions

  • Serviço de Hematologia Clínica. Hospital da Luz Lisboa. Lisboa. Portugal. & Faculdade de Medicina. Universidade Católica Portuguesa. Lisboa. Portugal.
  • Departamento de Hematologia Clínica. Unidade Local de Saúde de Coimbra. Coimbra. Portugal. & Centro Académico Clínico de Coimbra. Faculdade de Medicina. Universidade de Coimbra. Coimbra. Portugal.
  • Serviço de Hematologia e Transplantação de Medula. Unidade Local de Saúde de Santa Maria. Lisboa. Portugal.
  • Serviço de Hematologia. Instituto Português de Oncologia de Lisboa Francisco Gentil. Lisboa. Portugal.
  • Serviço de Hematologia. Unidade Local de Saúde de Braga. Braga. Portugal.
  • Serviço de Hematologia Clínica. Unidade Local de Saúde de São João. Porto. Portugal.

Cite

APA

Medina de Almeida, A., Marques, B., Polo, B., Pierdomenico, F., Dias, M., & Pinto, R. (2026). Practical Management of Cytopenias in Patients with Myelofibrosis Adapted to the Portuguese Reality. Acta Médica Portuguesa. https://doi.org/10.20344/amp.24397

Vancouver

Medina de Almeida A, Marques B, Polo B, Pierdomenico F, Dias M, Pinto R. Practical Management of Cytopenias in Patients with Myelofibrosis Adapted to the Portuguese Reality. Acta Médica Portuguesa. 2026. doi:10.20344/amp.24397

BibTeX
@article{MedinadeAlmeida2026,
  author = {Medina de Almeida, António and Marques, Bárbara and Polo, Blanca and Pierdomenico, Francesca and Dias, Marco and Pinto, Ricardo},
  title = {Practical Management of Cytopenias in Patients with Myelofibrosis Adapted to the Portuguese Reality},
  journal = {Acta Médica Portuguesa},
  year = {2026},
  doi = {10.20344/amp.24397}
}
Start for free →